Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053058 | 0.86 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13635818 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13602872 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL12730505 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL10192146 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7324089 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7324091 | 0.85 | CTSK (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL12018723 | 0.81 | CTSK (0.50) | CTSKCTSSCA2CA1CA7 | |
| Ammonia Solution, Strong SCHEMBL28313812 | 0.80 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL20039933 | 0.80 | CTSK (0.49) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | CTSK 3079/4885CTSS 3273/4885CA2 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.